Form 4: Adverum CEO Boosts Stake with Significant Stock Purchases

Adverum Biotechnologies' CEO and President, Laurent Fischer, acquired a substantial number of common shares in open market transactions in early December 2025.

Summary

• Laurent Fischer, CEO, President, and Director of Adverum Biotechnologies, Inc. (ADVM), reported two open market purchases of common stock.
• On December 5, 2025, Fischer purchased 11,085 shares at a weighted-average price of $4.24 per share, with prices ranging from $4.21 to $4.25.
• On December 8, 2025, Fischer purchased an additional 117,614 shares at a weighted-average price of $4.31 per share, with prices ranging from $4.25 to $4.32.
• Following these transactions, Fischer beneficially owns a total of 201,513 shares of Adverum Biotechnologies common stock.
• The total beneficial ownership includes 600 shares purchased on May 21, 2025, and 600 shares purchased on November 20, 2025, through the Issuer's 2014 Employee Stock Purchase Plan.

Sentiment

Score: 8

Explanation: The significant open market purchases by the CEO indicate strong insider confidence in the company's valuation and future prospects, which is generally viewed as a positive signal by investors.

Positives

• The CEO's significant open market purchases demonstrate strong confidence in the company's future prospects and valuation.
• Insider buying at these levels can often be interpreted by the market as a positive signal, suggesting management believes the stock is undervalued or poised for growth.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report (Form 4) primarily details personal stock acquisitions by a key executive and does not provide sufficient information to analyze broader industry trends or competitive positioning.

Comparison to Industry Standards

• A Form 4 filing, which reports insider transactions, does not typically provide data for direct comparison to industry-specific financial or operational benchmarks. Its primary purpose is transparency regarding executive stock ownership changes.

Stakeholder Impact

• Shareholders may view the CEO's increased stake as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.
• Employees might perceive this as a sign of stability and positive future outlook from leadership.

Key Dates

Recommendation

The substantial open market purchases by the CEO, Laurent Fischer, signal strong insider confidence in Adverum Biotechnologies' current valuation and future potential. Such significant insider buying is often a bullish indicator, suggesting that management believes the stock is undervalued or that positive developments are anticipated. While a Form 4 alone doesn't provide a complete investment thesis, it serves as a compelling signal for a 'buy' recommendation, particularly for investors looking for signs of conviction from company leadership.

Keywords

Adverum Biotechnologies, ADVM, Laurent Fischer, Insider Trading, Stock Purchase, CEO, Beneficial Ownership, Form 4